BNTXBioNTech SE
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Gross profit growth / assets (5 y)supports the score · percentile 92
- Volatility (1 y)weighs on the score · percentile 15
- Accrualssupports the score · percentile 94
Red flags and notes
- Caution:High leverage Net debt above 4× EBITDA or interest cover below 2×.
- Sources disagree Dividend or fundamental sources disagree beyond tolerance.
Our sources disagree or are incomplete for this instrument.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/B
- 1.0
- P/S
- 6.9
- Free-cash-flow yield
- 1.4%
- Market cap (EUR)
- €19.9B
Profitability and debt
- Return on equity
- −5.9%
- Gross margin
- 77.6%
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- −0.4%
- 1 month
- −10.3%
- 1 year
- −13.6%
- Volatility, 1 yr
- 46.4%
- Max drawdown, 1 yr
- −29.7%
- Beta
- 0.90
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
News and filings
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 14 Oct 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 19 Sep 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 14 Sep 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 28 Aug 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 28 Aug 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 20 Aug 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 4 Aug 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 4 Aug 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 3 Aug 2026
- BioNTech SE: 20-F/A (amendment) — Annual report of a foreign private issuer for the period ending 2025-12-31
FactSEC EDGAR · Filing · 31 Jul 2026
- BioNTech SE: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 30 Jul 2026
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | —/10 | — · — | Caution:High leverage | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.